These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Current status of autologous hematopoietic stem cell transplantation in myeloma. Mehta J; Singhal S Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S28-S34. PubMed ID: 18724294 [TBL] [Abstract][Full Text] [Related]
43. Recent trends in the management of newly diagnosed multiple myeloma. Reece DE Curr Opin Hematol; 2009 Jul; 16(4):306-12. PubMed ID: 19491669 [TBL] [Abstract][Full Text] [Related]
44. Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study. Ege H; Gertz MA; Markovic SN; Lacy MQ; Dispenzieri A; Hayman SR; Kumar SK; Porrata LF Br J Haematol; 2008 Jun; 141(6):792-8. PubMed ID: 18410454 [TBL] [Abstract][Full Text] [Related]
45. [Autologous stem cell transplantation in multiple myeloma - pro]. Goldschmidt H Dtsch Med Wochenschr; 2009 Sep; 134(39):1942. PubMed ID: 19760555 [No Abstract] [Full Text] [Related]
46. One or two autografts for myeloma? Mehta J Blood; 2008 Apr; 111(7):3899-900. PubMed ID: 18362216 [No Abstract] [Full Text] [Related]
47. Cellular immunotherapy for multiple myeloma. Rosenblatt J; Avigan D Best Pract Res Clin Haematol; 2008 Sep; 21(3):559-77. PubMed ID: 18790455 [TBL] [Abstract][Full Text] [Related]
48. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130 [TBL] [Abstract][Full Text] [Related]
49. Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study. Uy GL; Goyal SD; Fisher NM; Oza AY; Tomasson MH; Stockerl-Goldstein K; DiPersio JF; Vij R Bone Marrow Transplant; 2009 May; 43(10):793-800. PubMed ID: 19029964 [TBL] [Abstract][Full Text] [Related]
50. [The importance of autologous transplantation in multiple myeloma]. Pour L; Hájek R; Adam Z; Krejcí M; Vorlícek J Vnitr Lek; 2009 Sep; 55(9):767-72. PubMed ID: 19785373 [TBL] [Abstract][Full Text] [Related]
56. Eruption of lymphocyte recovery or autologous graft-versus-host disease? Nellen RG; van Marion AM; Frank J; Poblete-Gutiérrez P; Steijlen PM Int J Dermatol; 2008 Nov; 47 Suppl 1():32-4. PubMed ID: 18986483 [TBL] [Abstract][Full Text] [Related]
57. Idiopathic esophageal ulcers after autologous hemopoetic stem cell transplant: possible role of IgA levels. Dang S; Atiq M; Krishna S; Lamps LW; Olden KW; Aduli F Ann Hematol; 2008 Dec; 87(12):1031-2. PubMed ID: 18633617 [No Abstract] [Full Text] [Related]
58. Lymphocyte recovery: an overlooked contribution to autologous stem cell transplant outcome. Le Blanc K Cytotherapy; 2008; 10(5):441-2. PubMed ID: 18622799 [No Abstract] [Full Text] [Related]
59. Presence of serum carbonic anhydrase autoantibodies in patients relapsed after autologous stem cell transplantation indicates an improved prognosis. Lakota J; Skultety L; Dubrovcakova M; Altaner C Neoplasma; 2008; 55(6):488-92. PubMed ID: 18999876 [TBL] [Abstract][Full Text] [Related]
60. Current status and future directions in the treatment of multiple myeloma. Hou J; Wang M Chin Med J (Engl); 2007 Oct; 120(19):1651-4. PubMed ID: 17935663 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]